Fms like tyrosine kinase 3 (FLT-3) inhibitors & Acute myeloid leukemia (AML) (FLT3 m)

Although several aspects may challenge the use of FLT3 inhibitors in AML (resistance mechanisms, on- and off-target toxicities or drug-drug interactions), these drugs are generally well tolerated, particularly if we compare their safety profile with classical chemotherapy agents or even with newer immunotherapies, thus enabling their use in fit and unfit AML patients, alone or combined. As AML is a polyclonal disease and FLT3 mutations are a late leukemogenic event, combinations of these FLT3 inhibitors with other antileukemic agents (like venetoclax or hypomethylating agents) seem a necessary research pathway.
Solana-Altabella et al. 2022 Expert Opinion on Emerging Drugs 27(1): 1-18
…